Lipid Metabolic Reprogramming in Thyroid Cancer: Systemic Biomarkers, Tumor Dependencies and Therapeutic Resistance
- 1Department of Surgical Oncology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, No. 261 Huansha Road, Shangcheng District, Hangzhou 310006, China
- 2The Fourth Clinical Medical College, Zhejiang Chinese Medical University, No. 548 Binwen Road, Binjiang District, Hangzhou 310053, China
Abstract
Lipid metabolic reprogramming is increasingly implicated in thyroid cancer progression and treatment resistance alongside circulating lipid associations are often conflated with tumor lipid dependency. A clinically useful synthesis must distinguish systemic lipid markers from intratumoral lipid flux before integrating them into mechanistic or therapeutic models. This critical narrative review integrates evidence across three connected layers: circulating lipid markers; tumor-intrinsic uptake, oxidation, synthesis, desaturation, cholesterol and oxysterol pathways; and immune-spatial niches involving macrophage lipid handling, APOE-associated polarization and ferroptosis-related lipid peroxidation. In papillary thyroid carcinoma, multi-omics and mechanistic studies implicate LPL-FATP2-CPT1A, PC-AKT/mTOR-SREBP1c-FASN and METTL16/YTHDC2/SCD1 programs in membrane remodeling, invasion-related behavior and recurrence risk stratification. In aggressive and anaplastic thyroid cancer, cholesterol synthesis signaling, fatty acid oxidation adaptation and SREBF1/SCD1-linked ferroptosis defense may contribute to resistance to radioiodine, radiotherapy, chemotherapy and BRAF/MEK inhibition. The current evidence is strongest for mechanistic and biomarker hypotheses; thyroid-cancer-specific prospective trials of lipid-directed treatment are lacking. Lipid metabolism therefore provides a framework for molecular stratification and treatment sensitization, but it does not currently justify nonspecific lipid lowering or routine lipid-targeted therapy. Translation will require paired blood and tumor lipidomics, spatial profiling, functional perturbation and biomarker-defined prospective studies.
Related
- CD36-Mediated Lipid Metabolic Reprogramming in Hepatocellular Carcinoma: Crosstalk With Immunity, Ferroptosis, and Therapeutic Resistance.
- Decoding lipid metabolic reprogramming in pancreatic ductal adenocarcinoma: from tumor–microenvironment crosstalk to therapeutic resistance
- Lactate-driven metabolic-epigenetic reprogramming in breast cancer: immune evasion and therapeutic resistance.
- FluxAtlas is a pan-cancer metabolic flux atlas that identifies tumor-selective dependencies and prognostic biomarkers
- L-histidine metabolic reprogramming is associated with imipenem-relebactam resistance in carbapenem-resistant hypervirulent Klebsiella pneumoniae
BibTeX
@article{zhou2026lipid,
title = {{Lipid Metabolic Reprogramming in Thyroid Cancer: Systemic Biomarkers, Tumor Dependencies and Therapeutic Resistance}},
author = {Li Zhou and Yiqing Mi and Linlin Mao and Jingjing Shi and Yu Zhang and Gang Pan and You Peng},
journal = {Metabolites},
year = {2026},
month = sep,
doi = {10.3390/metabo16100736},
url = {https://www.mdpi.com/2218-1989/16/10/736},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Lipid Metabolic Reprogramming in Thyroid Cancer: Systemic Biomarkers, Tumor Dependencies and Therapeutic Resistance
AU - Li Zhou
AU - Yiqing Mi
AU - Linlin Mao
AU - Jingjing Shi
AU - Yu Zhang
AU - Gang Pan
AU - You Peng
PY - 2026
DA - 2026/09/30
JO - Metabolites
DO - 10.3390/metabo16100736
UR - https://www.mdpi.com/2218-1989/16/10/736
AB - Lipid metabolic reprogramming is increasingly implicated in thyroid cancer progression and treatment resistance alongside circulating lipid associations are often conflated with tumor lipid dependency. A clinically useful synthesis must distinguish systemic lipid markers from intratumoral lipid flux before integrating them into mechanistic or therapeutic models. This critical narrative review integrates evidence across three connected layers: circulating lipid markers; tumor-intrinsic uptake, oxidation, synthesis, desaturation, cholesterol and oxysterol pathways; and immune-spatial niches involving macrophage lipid handling, APOE-associated polarization and ferroptosis-related lipid peroxidation. In papillary thyroid carcinoma, multi-omics and mechanistic studies implicate LPL-FATP2-CPT1A, PC-AKT/mTOR-SREBP1c-FASN and METTL16/YTHDC2/SCD1 programs in membrane remodeling, invasion-related behavior and recurrence risk stratification. In aggressive and anaplastic thyroid cancer, cholesterol synthesis signaling, fatty acid oxidation adaptation and SREBF1/SCD1-linked ferroptosis defense may contribute to resistance to radioiodine, radiotherapy, chemotherapy and BRAF/MEK inhibition. The current evidence is strongest for mechanistic and biomarker hypotheses; thyroid-cancer-specific prospective trials of lipid-directed treatment are lacking. Lipid metabolism therefore provides a framework for molecular stratification and treatment sensitization, but it does not currently justify nonspecific lipid lowering or routine lipid-targeted therapy. Translation will require paired blood and tumor lipidomics, spatial profiling, functional perturbation and biomarker-defined prospective studies.
SN - 2218-1989
ER -